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Peripheral blood lymphocyt~s of33 ~atients with histopatho-
logic confirmation of mycos1s fung01des and 27 healthy con-
trols matched for age and sex were analyzed with a panel of 
monoclonal antibodies using both single and dual color 
immunofluorescence. Patients with mycosis fungoides had 
a significant reduction in the percentage of circulating 
T cells with a naive phenotype (i.e., CD4+2H4+ and 
CD4+Leu8+), as well as a significant reduction in the abso-
T he spectrum of diseases grouped within the classifica-tion cutaneous T-cell lymphoma (CTCL) includes the clinical syndromes of mycosis fungoides (MF) and Sezary's syndrome (SS) (1]. In SS, the presence of lymphocytosis and circulating mononuclear cells 
with cerebriform nuclei identify the malignant clone. In contrast, 
the morphology of most circulating lymphocytes in MF is usually 
normal l2,3]. 
The study of cell-surface antigens using monoclonal antibodies 
has lead to a greater understanding of leukocyte ontogeny and lym-
phoproliferative disorders. Analysis of infiltrating lymphocytes in 
MF has shown that the malignant cells are usually of the CD4 
(helper) T-cell subset (4-8]. There has been no unigue phenotypic 
profile found that is characteristic of the MF cell (9], although it is 
known that as cellular atypia becomes more marked, normal T-cell 
antigens may be lost (10-12]. 
There have only been a limited number of studies that have exam-
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Abbreviations: 
BSA PBS: bovine serum albumin in phosphate-buffered saline 
Con A: concanavalin A 
CTCL: cutaneous T-cell lymphoma 
FACS: fluorescence-activated cell sorter 
LAMl: leukocyte adhesion molecule 1 
MF: mycosis fungoides 
NM: nitrogen mustard 
PBL: peripheral blood lymphocytes 
PBMN: peripheral blood mononuclear cells 
PE: phycoerythrin 
PHA: phytohaemagglutinin 
PUVA: psoralen and ultraviolet A 
SALT: skin-associated lymphoid tissue 
SS: Sezary's syndrome 
TS: topical steroids 
lute numbers of circulating lymphocytes with the phenotype 
CD8+Leu8+ compared to the control cohort. The reduction 
in circulating naive T cells was found to occur irrespective of 
stage of disease, duration of disease, or mode of treatment. 
The depletion of circulating naive T cells may reflect in-
creased conversion to memory T cells in the peripheral blood 
or skin.] Invest Dermato/96:50-56, 1991 
ined peripheral blood lymphocytes (PBL) for immunophenotypic 
abnormalities in MF. These studies used flow cytometry with sin-
gle-color analysis of lymphocyte subsets and revealed conflicting 
results with regard to CD4 expression (13-15]. We therefore un-
dertook further examination ofT lymphocyte subsets using dual-
color analysis, which permits the examination of two surface anti-
gens simultaneously. 
Analysis ofPBL in early-stage MF may be useful for two reasons. 
First, it may lead to an explanation of why systemic immunologic 
abnormalities exist in early-stage MF (16]. Second, it may help show 
that there exists a pool of lymphocytes within the peripheral blood 
that either interacts with the cutaneous infiltrate or is actually part 
of the malignant proliferation itself. 
In order to address these issues, we examined the PBL of 33 
patients with MF and 27 healthy controls matched for age and sex 
with a panel of monoclonal antibodies using both single- and dual-
color immunofluorescence. 
MATERIALS AND METHODS 
Patients Thirty-three patients with histopathologic confirma-
tion of MF (15 men, 18 women, mean age 60 years) were investi-
gated after obtaining informed consent. A full medical history was 
taken and clinical examination performed. For the purposes of sta-
tistical analysis, patients were grouped into one of three categories 
with regard to staging (1, patches; 2, plaques; or 3, advanced dis-
ease); into one of four categories with regard to most aggressive 
treatment (1, nil; 2, topica) steroids; 3, topical nitrogen mustard; or 
4, psoralens and ultraviolet A); and into one of two categories with 
regard to duration of documented disease ( 1, less than 10 years or 2, 
greater than 10 years). Table I shows the number of patients within 
each category. Table II lists the TNM stage of disease, the percent-
age of skin involvement, and the current or past treatment for each 
patient. Patients with circu lating Sezary's cells were excluded from 
the study by cytologic examination of peripheral blood smears. Pa-
tients were studied irrespective of previous or intercurrent treat-
ment and all patients had clinical evidence of MF at the time of 
examination and venesection. 
Twenty-seven healthy volunteers matched for age and sex (1 4 
men, 13 women, mean age 59 years) were used as controls. These 
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Table I. Clinical Definitions Used in Statistical Analysis and 
Patient Numbers 
Stage of disease 
1. Patch 
2. Plaque 
3. Pathologic lymphadenopathy, skin 
tumors or visceral involvement 
Duration of Disease 
1. < 10 years 
2. > 10 years 
Most Aggressive Treatment 
(past or present) 
1. Nil• 
2. Topical steroidsb 
3 . Topical nitrogen mustard' 
4. PUVN 
Number of Patients 
in Each Category 
23 
5 
5 
23 
10 
6 
16 
5 
6 
• No treatment in 12 months prior to venesection or topical betamethasonc dipro-
pionate prior to 3 months of venesection. 
b Topical betamethasone dipropionate within 3 months of venesection. 
' Treatment within 12 months of venesection. 
J Treatment within 12 months of venesection. Includes 1 patient who also received 
topical betamethasone dipropionate, 2 patients who also received topical nitrogen 
mustard, and 1 patient who also received topical betamcthasonc dipropionatc, topical 
nitrogen mustard, and systemic chemotherapy. 
subjects had no evidence of either immunologic or malignant dis-
ease. 
Isolation of Lymphocytes Human peripheral blood mononu-
clear cells were isolated from heparinized venous blood by Ficoll-
H ypaque gradient density centrifugation (Pharmacia Fine Chemi-
cals, Piscataway, NJ) . 
Monoclonal Antibodies The monoclonal antibody panel used 
in the study is shown in Table III . Monoclonal antibodies used 
included fluorescein-conjugated anti-CD4 and anti-CD8 (Ortho 
Diagnostics, Raritan, NJ), as well as Leu8 (Becton Dickinson, 
Mountain View, CA). Phycoerythrin (PE)-conjugated anti-CD4, 
anti-CD8, 4B4, 2H4, and anti-HLA-DR (Coulter Clone, Hialeah, 
FL) were used, in addition to anti-CD25 (Becton Dickinson). Un-
conjugated monoclonal antibodies included anti-CD2 and anti-
CD11B (Ortho Diagnostics), as well as anti-CD7, anti-CD16, 
anti-CD20, anti-CD57, and LeuM1 (Becton Dickinson). Anti-
CD3 was obtained from supernatants of an OKT3-producing hy-
bridoma cell line. Fluorescein-conjugated sheep anti-mouse immu-
noglobulin (Silenus, Melbourne, Australia) was used to label 
monoclonal antibodies not directly conjugated to fluorochrome. 
Purified mouse immunoglobulin co~ugated to either fluorescein or 
PE was used to control for nonspecific binding. 
Cell Staining Cells were washed twice with 2% bovine serum 
albumin in phosphate-buffered saline (2% BSA PBS) and adjusted to 
a final concentration of 20 million per mi. Fifty microliters of this 
cell suspension (1 million cells) were incubated with saturating 
concentrations of monoclonal antibody for 15 min at 4°C and 
washed once more with 2% BSA PBS. Monoclonal antibodies not 
conjugated to a fluorochrome were then incubated with fluores-
cein-conjugated sheep anti-mouse immunoglobulin. All monoclo-
nal antibodies used in dual-color immunofluorescence were directly 
labeled to a fluorochrome. Thus, double staining could be per-
formed as a single-step procedure. Cells were then washed twice 
w ith 2% BSA PBS and fixed for flow cytometry in 2% BSA PBS 
w ith 1% formaldehyde. 
Flow Cytometry Flow cytometry was performed with a fluores-
cence-activated cell sorter (FACS II or FACScan, Becton Dickin-
son) with either single- or dual-color analysis. Cells were gated on 
forward and right-angle light scatter for lymphocytes to minimize 
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Table II. TNM Staging, Percentage of Skin Involvement and 
Current or Past Treatments for .Each Patient" 
Percentage of Current 
Patient TNM Stageb Skin Involvement Treatment 
1 Ia <5% Nil'·' 
2 I a <5% Nil' 
3 I a 5 - 10% TS 
4 Ia < 5% TS 
5 I a 5-10% TS' 
6 Ia < 5% Nil 
7 I a 5-10% TS 
8 I a 5-10% TS'·' 
9 I a 5-10% TS 
10 !a 5 - 10% TS 
11 I a 5 - 10% TS 
12 Ia < 5% Nil• 
13 I a <5% Nil' 
14 I a 5% Nil' 
15 I a < S% TS 
16 I a < 5% Nil 
17 I a < 5% Nil• 
18 I a < S% TS 
19 I a < 5% Nil' 
20 I a 5 - 10% Nil' 
21 I a < S% Nil 
22 Ib 15% TS 
23 Ib 10% Nil 
24 Ib 10% NM 
25 Ib 10% Nil 
26 Ib 50% TS 
27 II a 5-10% TS 
28 II a 5-10% Nil' 
29 Ub nodule NM 
30 lib nodule Nil 
31 lib 15% Nil'·' 
32 IVa 10% Nil' 
33 IVa 30% Chemotherapy'·' ·' 
• TS, Topical sterioids. In all cases, patients were using betamethasone dipropionate 
0.05% cream or ointment. NM, Topical nitrogen tnustard. 
' As adopted by the Mycosis Fungoidcs Cooperative Group. 
' Patients who had received psoralen and ultraviolet A therapy (PUVA) within 12 
months of venesection. 
' Patients who had used topical betamethasone dipropionate 0.05% cream or oint-
ment within 3 months of venesection. 
• Patients who had received topical nitrogen mustard within 12 months of venesec-
tion. 
the inclusion of other leukocytes in the ~ell count. In each analysis, 
10,000 cells were counted and screened as positive or negative ac-
cording to their fluorescence with reference to that of control sam-
ples. The number of positive cells was expressed as a percentage of 
the total lymphocytes counted. In single-calor studies, this percent-
age was derived by the use of a computer program, whereas com-
puter-generated two-dimensional dot plots were used in two-color 
studies. 
A differential white cell count was used in conjunction with 
percentage results to calculate absolute lylllphocyte numbers. 
Statistics Unpaired two-tailed t tests were performed using a 
computer statistics package (Stat Works, Cricket Software, Inc., 
Philadelphia, PA) to compare both percentages and absolute cell 
counts between patient and control groups . A one-way analysis of 
variance was used to examine the level of association between clini-
cal parameters and immunophenotypic data. 
RESULTS 
Cell-surface antigen expression of lylrlphocyte subpopulations in 
patients with MF and normal controls using single and dual color 
immunophenotyping are summarized in Tables IV, V, and VI. The 
data is presented as percentage of positive cells and absolute numbers 
of cells for each surface antigen or antigen combination. Data were 
able to be presented as percentage of positive cells, as the fluores-
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Table III. Monoclonal Antibody Panel 
Antibodies CD Designation Predominant Specificity 
OKT11 C02 PanT cell 
Anti CD3 CD3 PanT cell 
OKT4 or T4 CD4 Helper T cell (70-90% T cells in 
PBL) 
Leu9 CD7 Majority T cells 
OKT8 orT8 CDS Suppressor/cytotoxic T cells (15-
30% T cel ls in PBL) 
OKMl CDllB Monocytes /granulocytes 
Leu Ml CD15 Mon ocytes/ granulocytes 
Leu 11 CD16 N a rural killer cells 
Leu 16 CD20 Pan B cell 
TAC CD25 lnterleukin-2 receptor 
Anti HLA-DR B cells, activated T cells 
4B4 CDw29 Part of VLA family of adhesion 
molecules; memory T cells 
2H4 CD45R Highest molecular weight forms of 
CD45; naive T cells 
Leu7 CD 57 NK cells 
Leu8 Majority T cells, majority B cells; 
some granulocytes, monocytes 
and NK cells 
cence intensity of the patient histograms did not differ from normal 
controls. 
There was no significant difference between the total number of 
peripheral blood mononuclear cells in healthy controls and in the 
patients with MF. 
Single-color analysis showed a significant reduction in the per-
centage of lymphocytes expressing the CD4 (p < 0.01) and LeuS 
(p < 0.0001) antigens in patients with MF, as compared to healthy 
controls. The percentage of cells expressing CDS and the CD4/ 
CDS rati9 in patients were not significantly different from controls. 
To further characterize the percentage depletion of CD4 and 
LeuS expression, cells were examined by dual staining. Patients 
with MF had a significant reduction in the percentage of lympho-
cytes with the phenotype CD4+LeuS+, CD4+2H4+, and 
CDS+LeuS+, as compared to healthy controls (p < 0.0001 in all 
cases). Furthermore, there was a depletion in the absolute numbers 
of lymphocytes coexpressing CDS and LeuS antigens (p < 0.05). 
The percentage of lymphocytes with the phenotype CD4+4B4+, 
CDS+2H4+, and CD8+4B4+ in patients with MF was not signifi-
cantly different from that of controls. 
Statistical analyses were performed with the single-color panel on 
surface antigens other than CD4, CDS, and LeuS using laboratory 
normals as contro ls. These data are shown in Table V. This panel 
Table IV. Single Color lmmunophenotyping in Patients w ith 
Mycosis Fungoides and in Control Subjects 
Healthy Patients with 
Controls Mycosis Fungoides 
n = 27 n = 33 
Age (range) Years 59 (43-78) 60 (36-82) 
Sex F/M 13/14 18/15 
PBMN• Cells/mm3 1500 ± 140 1580 ± 140 
CD4 +Cells % 51 .6 ± 2.2 41.7 ± 2.5b 
Cells/mm3 740 ± 60 690 ± 80 
CDS+ Cells % 20.7 ± 1.7 19.3 ± 1.5 
Cells/mm3 370 ± 60 290 ± 20 
Leu8 +Cells % 61.1±4.1 34.3 ± 5.1' 
Cells/mm3 950 ± 120 740 ± 140 
CD4/CD8 Ratio 3.22 ± 0.4 2.61 ± 0.2 
• PBMN denotes peripheral blood mononuclear cells. Values shown are the 
mean± SEM. 
6 p < 0.01 as compared with healthy controls (two-tailed t test). 
' p < 0.0001 as compared with healthy controls (two-tailed t test). 
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included panT-cell markers (anti-CD2, anti-CD3, and anti-CD7), 
pan B-cell markers (anti-CD20), monocyte and granulocyte 
markers (anu-CD11B and CD15), and natural killer cell markers 
(anti-CD57 and anti-CD16), in addition to anti-HLA-DR and anti-
CD25. Patients with MF were found to have decreased percentage 
expressiOn of the CD2, CD3, and CD7 antigens on PBL, as well as 
decreased numbers of circulating lymphocytes expressing these an-
tigens, as compared to the controls (p < 0.01 in all cases). The 
percentage of cells expressing HLA-DR antigen on circulating lym-
phocytes 1n MF was found to be increased as compared to the con-
trol ~ohort (p< 0.01). This latter result probably reflects the rela-
tive mcrease m B cells due to a reduction in T cell numbers in 
patients with MF. The differences in expression of CD11b, CD 57, 
CD15, CD20, CD16, and CD25 on circulating PBL in MF and 
controls was not significant at the 5% level. 
Fi_gures ~' 2, .and 3 show the distribution of percentage values 
obtamed wtth smgle- and dual-color analysis in patients with MF 
plotted next to the values obtained for the healthy controls. The 
shaded area represents that part of the distribution less than two 
standard deviations below that of the control mean; therefore, any 
value found in this area can be regarded as below normal. Twelve 
patients with MF had a selective decrease in the percentage of circu-
latmg lymphocytes exl?ressing LeuS antigen, whereas six patients 
had a selective decrease m the percentage oflymphocytes expressing 
CD4. Nme patients had a selective reduction in the percentage of 
lymphocytes coexpressing CD4 and LeuS antigens. In contrast, 
only one of .27 controls were found to have reduced percentage of 
cells expressmg Leu8 and none of the 27 controls had either reduced 
populations of CD4+ cells or CD4+LeuS+ cells. 
Using dual-color immunofluorescence, we also examined CD4 
and CDS cells for coexpression of antigens HLA-DR and CD 25. 
We found that circulating CD4 or CD8 T cells in both MF and in 
healthy controls do not express these activation antigens. 
. We examined the relationship between the clinical parameters of 
d1sease stage and duration and mode of treatment with the PBL 
~mmunophenotype using a one-way analysis of variance. We exam-
me~ the data with regard to CD4, CDS, and LeuS expression, in 
additiOn to the dual-color results obtained for CD4/2H4, 
CD4/4B~, CD4/L~uS, CDS/2H4, CDS/4B4, and CD8/Leu8 
coexpr~ss.!On. Each unmunophenotypic profile was analyzed with 
each .ch.mcal. parameter, generating 27 p values. In all cases, the 
association d1d not reach statistical significance at the 5% level (data 
not shown). 
DISCUSSION 
The r.esults of this study demonstrate that PBL from patients with 
MF d1ffer from PBL of normal age- and sex-matched controls with 
respect to lymphocyte surface antigen expression. We have shown 
that the percentage of circulating lymphocytes with the phenotype 
CD4+2H4+, CD4+LeuS+ , and CDS+LeuS+ are decreased in 
MF. This depletion is reflected in single-color analysis because the 
percentages of CD4+ lymphocytes and Leu8+ lymphocytes are 
also reduced. 
Recently, the classification ofT lympHocytes as either naive or 
memory cells h~s simplified our understanding ofT -cell biology, as 
we~l as mtegratmg current knowledge regarding changes in surface 
antigen express101~ following T -cell activation. There are many 
T-cell surface antigens that are known co be either up or down 
regulated followmg exposure to antigen [17 ,1S]. 2H4 and LeuS are 
examples of monoclonal antibodies that recognize surface determi-
nants on T cells that .are down regulated on exposure to antigen 
[ 1S, 19], whereas 4B4 ts a monoclonal antibody recognizing an epi-
tope that 1s up regulated upon antigen exposure [18] . It has been 
proposed that lymphocytes with the phenotype CD4+2H4+ or 
CD4+LeuS+ are naive T cells and those with the phenotype 
CD4+4B4+ or CD4+L~uS- are memory T cells [18,19]. Our 
demonstratiOn of a depletwn ofT -cell subsets with the phenotype 
CD4+2H4+ and CD4+Leu8+ indicates that naive T cells are un-
derrepresented in the peripheral blood of patients with MF. Tl1is 
depletion of naive lymphocytes in the peripheral blood is not spe-
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Table V . _D ual-Color Immunophenotyping in Patients with Mycosis Fungoides and in Control Subjects" 
Age (range) 
Sex 
PBMN 
CD4 + 2H4 +Cell s 
CD4 + 4B4 +Cel ls 
CD4 + LeuS + Cells 
CDS + 2H4 + Ce lls 
CDS+ 4B4 +Cells 
CDS + LeuS + Cel ls 
.. Values shown arc the mea n ± SEM. 
Years 
F/M 
Ce lls/mm' 
% 
Cells/mm3 
% 
Cells/mm3 
% 
Cells/mm3 
% 
Cells/mm' 
% 
Cel ls/mm' 
% 
Cells/mm3 
b p < 0.0001 as compared with healthy controls {two-rai led r rest). 
' p < 0.05 as compared with healthy controls (two-railed r test). 
cific for M F. Similar results have been seen in th e PBL of patients 
with rheumatoid arthritis [20], systemic lupus erythematosis [21], 
and multiple sclerosis (22], and probably refl ects th e altered ac tiva-
tion status o f the circulatin g T ce lls [23]. 
It is thought that in the normal state th ere is a constant circulation 
of lymphocytes th rough the skin, draining lymph nodes, peripheral 
blood, and spleen, and th at this migration of lymphocytes provides 
immunologic surveillance for the skin [24]. This is referred to as the 
skin-associated lymphoid tissue (SALT) . It is possible that in pa-
tients w ith M F, lesional skin could interac t w ith the circulating 
lymphocytes and alter th eir surface antigen expression before they 
m igrate back to peripheral blood. The re lative depletion of T cells 
w ith a naive phenotype in the peripheral blood of patients w ith MF 
may refl ect the fac t that naive T cells that are circulating through 
SALT are preferentially retained in lesional skin. This retention 
may be due to an ongoing infl ammatory response to the cutaneous 
malignancy, or may be secondary to the malignant T cells w ithin 
the cutaneous infi ltrate secreting lymphokines that are chemotactic 
Healthy Contro ls 
n = 27 
59 (43-7S) 
13/14 
1500 ± 140 
19.0 ± l.S 
230 ± 40 
26.6 ± 1.2 
3SO ± 40 
41.4 ± 2.6 
550 ± 60 
12. 1 ± 1.3 
210 ± 40 
15.6 ± 1.7 
2SO ±so 
9.S ± o.s 
170 ± 20 
Patients with 
Mycosis Fungoides 
n= 33 
60 (36-S2) 
1S/15 
15SO ± 140 
S.4 ± 1. Sb 
160 ± 40 
24.5 ± 1.S 
420 ±so 
23.0 ± 2.Sb 
430 ± 70 
12. 1 ± 1.1 
210 ± 30 
14.2± 1.4 
220 ± 30 
5. 1 ± 0 .7b 
90 ± 10' 
for the naive circulating T cel ls. In support of this latter hypothesis, 
it has been shown that tissue levels of interl eukin-1 , a lymphokine 
that is a chemotactic and an activating fac tor for T cells, are in-
creased in lesional skin of patients w ith MF (25]. Once the T cell s 
reach the tn icroenvironment of the skin , they may become activated 
and thus lose the surface an tigens recognized by 2H 4 an d Leu8. 
Some of these activa ted T cells could subsequently recirculate, thus 
accounting for the preponderance of T cells in peripheral blood 
with a memory-cell phenotype. This model not only explains our 
findin gs of the relative lack ofT cells with a naive phenotype in M F, 
but is also in agreement w ith the observed lack of expression of 
Leu8+ lymphocytes in the cutaneous lesions of MF [26-29]. 
A new family of cellular adhesion/ homing molecules has re-
cently been identified by eD NA cloning. These molecules have 
been called "selectins" because of the presence of a lectin domain 
and their ro le in selective cel l trafficking (30] . A member of this 
fa mily expressed on human lymphocytes is the leukocyte ad hesion 
molecule 1 (LAM1) . It has recently been demonstrated that the 
Table VI. Single-Color Immunophenotyping in Patients with Mycosis Fungoides and in Laboratory Controls" 
CD2 + Cel ls o/o 
Cells/mm' 
CD3 + Cells % 
Cells/mm3 
CD7 +Cells % 
Cells/mm> 
CD 11b +Cells % 
Cells/mm' 
CD1 5 + Cells 
CD16 + Cells % 
Cells/mm3 
CD20 +Cells % 
Cells/mm3 
CD25 + Cells 
CD57 + Cells % 
Cclls/mm' 
HLA-DR + Cells % 
Cells/mm3 
• Values shown arc the mean± SEM. 
' n = 33 in patients wi th mycosis fungoides. 
'p < 0.05 as compared with laboratory controls (two-tailed t test). 
' p < 0.01 as compared with laboratory controls (two tailed t tes t) . 
Laboratory Controls 
SO.O ± 0.9 11 = 48 
1590 ± 66 n = 39 
69.6 ± 1.0 11 = 75 
1400 ± 46 n = 62 
76. 1 ± 1.5 11 = 39 
1490 ± 70 11 =39 
17.5 ± 1.0 11 = 66 
430 ± 36 n = 66 
Not expressed n = 13 
11.9± 1.1 n = 45 
250 ± 32 n = 37 
11.9± 0.6 n =44 
240 ± 20 11 =37 
Not expressed 11 = 16 
11.0 ± 1.0 n =51 
220 ± 22 n = 44 
13.S ± 0.7 11 =5 1 
2SO ± 21 11 = 4S 
Patients with 
Mycosis Fungoides• 
75.7 ± 2.0' 
11 90 ± 120" 
63.5 ± 2.4' 
1040 ± 11 0' 
66 .1 ± 3.4' 
1030 ± 100' 
22.4 ± 2.2' 
300 ± 24 
Not expressed 
13.3 ± 1.4 
1SO ± 15 
13.4 ± 1.9 
220 ± 62 
Not expressed 
12.9 ± 1.5 
l SO ± 19 
l S.S ± 1.6' 
260 ± 45 
54 GILMORE ET AL 
100 
... 
... 
., 
- 80 ::::>'> u 
0 
• .&: 
., 
-::70 0 
0 
.&: 
0. 
0. • E n • ::::>'> 60 .....J + • '<t" 1:. 0 u 
.... 40 a. 0 • ., 
• • "" ... :~:: 
-
c 
., 20 : ~: u 
..... ~ ~ : ~ ., a.. : ~ : : 
E 
::70 
...... 
+ 
to 
0 
u 
.... 
0 
... 
"" .:?, 
c 
... 
0 ,_ 
., 
a.. 
0 
Controls Pati~nts 
100 
80 
60 
40 • 
• I ~ .. If 20 
0 
Controls Patients 
. THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
100 
"' 
., 
-~ 8 0 
0 
.&: 
0. 
E 
::70 
...J 
€.0 
+ 
to 
:::> 
... 
...J 
.... 40 0 
... 
"" ... c 
... 20 0 ,_ 
... 
a.. 
0 
• 
• 
l 
•  
• 
.. 
t. 
* 
• 
• 
_._ 
:~: 
• 
.. 
• .. 
• 
• 
• ~ 
• 
Figure 1. Percentage of cells stained with single-colored antibodies in patients with mycosis fungo ides and in controls. The slzaded area indicates the area I 
outside the mean minus two standard deviations of the control populat1on. CD4 and Leu8 expression was significancly lower in the patients with mycosll 
fungoides as compared to controls. 
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Figure 3. Percentage of cells stained with dual-colored antibodies in patients with mycosis fungoides and in controls. CD8Leu8 expression was significant\) 
lower in patients with mycosis fungoides as compared to controls. 
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pattern of reactivity of anti-L~Ml antibody is identical to that. of 
Leu8 antibody and that a reductiOn of LAM 1 expressiOn occurs w1th 
mitogen stimu lation, with a consequent loss of abi lity of the treated 
lymphocytes to bind to lymph node high endothelial venules (30]. 
It was suggested that LAM 1 may participate in the process ofleuko-
cyte extravasation into lymphoid organs or sites of acute inflamma-
tion with subsequent loss ofLAM1 from the surface (30]. As Leu8 
and LAM1 share identical patterns of reactivity to monoclonal anti-
bodies, it is possible that Leu8-positive CD4lymphocytes preferen-
tially bind to endothelium in the lesional skin of patients with MF 
with subsequent loss of Leu8 expression. 
Sequestration of naive T cells in the skin is not the only J?Ossible 
mechanism that can account for an excess of memory T cells 111 PBL. 
First, naive T cells may assume the phenotype of a memory cell at 
extracutaneous sites such as peripheral blood or lymph node. Sec-
ond, it is possible that th e depletion of naive T cells in peripheral 
blood is due to the presence of circulating malignant cells with the 
phenotype of a ~emory T cell. It is thus possible that malignant T 
cells are circulat111g through sk111, lymph node, and penpheral blood 
in early-stage disease. We are currently examining this hypothesis 
by Southern blot analysis of the DNA from the cells in the periph-
eral blood. Weiss eta! (31] examined the PBL of 26 patients with 
MF and SS and found gene rearrangements of the T-cell receptor, 
indicating the presence of a clonal proliferation ofT lymphocytes, 
in seven of these patients. Interestingly, three of these seven patients 
had no morphologically detectable atypical lymphocytes in their 
blood. 
It has been established that systemic immunologic abnormalities 
exist in early-stage MF [16]. In vitro studies performed on PBL by 
Langner et al (32] showed modest decreases in PH~ re.sponses. in 
peripheral blood mononuclear cell s from patients w1th 111filtrattve 
MF. In other studies, N orris [1 6] examined the stimulation indexes 
of peripheral blood mononuclear cells of patients with early-stage 
MF when cultured for 5 d with mitogen and an interleukin-1-like 
growth factor. Significantly and co.nsistently depressed s~imulation 
indexes were seen, as compared w1th controls. Our findmgs show 
rhat in addition to these abnorma lities of lymphocyte cell function, 
phenotypic abnormalities of the PBL are also present in MF. Inter-
estingly, recent 111 v1tro studies show that the CD4+4B4+ subset of 
T lymphocytes (the memory T cells) are poor responders to the 
mitogens PHA and ConA (33] . Some of the early results regarding 
depressed mitogenic stimulation of peripheral blood mononuclear 
cells may therefore be attributable to an increased ratio of memory 
to naive T cells in the PBL of patients with MF. As memory T cells 
provide the help to B cells for immunoglobulin production [18], an 
increase in the ratio of these cells to naive T cells in the peripheral 
blood may account for the monoclonal gammopathies of IgA and 
IgE that have been reported in MF (34]. 
This study shows that patients with MF have a relative depletion 
of T cells in the peripheral blood with the naive phenotype 
CD4+2H4+ and CD4+Leu8+, in comparison with age-matched 
controls. There is a need for further studies to explore the possible 
mechanisms and implications of these phenomena. 
We acktJOwledge the assista11ce oft he ma11y dermatologists i11 Melboume wlro ki11dly 
provided patie11ts for the study, i11 particular Dr. Han1ey Rotstei11 of St. Vi11cwts 
Hospital, for al/owi11g us to access the patie11ts attwding the dermatology cli11ic. 
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ANNOUNCEMENT 
The International Workshop on Hyperthrophic Osteoarthropathy will be held September 
9-11, 1991 in Dubrovnik, Yugoslavia. 
Organizers: Professor Ivo J ajic, M .D., D .Sc., Yugoslavia; Marco Matucci-Cerinic, M.D., 
Ph .D., Italy; and Manuel Martinez Lavin, M.D., Mexico. 
Sponsors: EULAR, The Yugoslav Association of Rheumatology, and the Medical Associa-
tion of Croatia. 
Scientific Program: epidemiologic, genetic, patl;ologic, clinical, and roentgenologic aspects 
of disease and treatment. 
For information contact Professor Ivo Jajic, Secretariat of International Workshop on 
Hyperthrophic O steoarthropathy, D epartment of Physical Medicine and Rheumatology, 
Lovcenska 100, 41000 Zagreb, Yugoslavia. 
